Study shows benefits of epilepsy drug eslicarbazepine acetate
A study has underlined the potential benefits offered by the antiepileptic drug eslicarbazepine acetate (ESL).
Appearing in the journal Epilepsy Research, the Spain-based ESLIBASE retrospective study aimed to evaluate the long-term efficacy and safety of ESL in patients with focal seizures over a period of one year.
In total, 327 patients were included in the study, with 78 per cent of them taking two or more other AEDs at baseline. 87 per cent began ESL treatment because of poor seizure control and 13 per cent because of adverse events experienced when receiving carbamazepine (CBZ) and oxcarbazepine (OXC).
After one year, 72.4 per cent remained on ESL, with 52.5 per cent of them remaining responsive to treatment after 12 months – moreover, 25.3 per cent were seizure-free. Response rates significantly increased when ESL was combined with a non-sodium channel-targeting drug, while those who switched from CBZ or OXC tended to tolerate ESL better.
The paper concluded: “ESL was well-tolerated and effective in a real-world setting over one year. Side-effect profile improved when OXC and CBZ recipients were switched to ESL.”
Eslicarbazepine acetate has been available in Europe since April 2009 and is often prescribed as an add-on therapy for adult patients with partial-onset seizures, with or without secondary generalisation.
Posted by Steve Long